SHR-RAS001
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Discovery and identification of SHR-RAS001: A structurally novel, highly potent tri-complex RASmulti(ON) inhibitor
(AACR 2026)
- "It demonstrates potent antitumor activity along with favorable pharmacokinetic and safety profiles. An open-label, multicenter Phase I study of SHR-RAS001 is currently underway."
Late-breaking abstract • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS
1 to 1
Of
1
Go to page
1